Company description

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company that focuses on developing and commercializing innovative therapies that address rare and serious diseases. Founded in 1986, the company is headquartered in Durham, North Carolina and has a global presence, with offices in the United States, United Kingdom, and Australia. BCRX's goal is to improve the lives of patients by providing treatments for rare diseases and unmet medical needs that currently have limited or no available treatment options. The company's flagship product, Orladeyo, is approved in the United States and Europe for the prevention of hereditary angioedema attacks. BCRX's pipeline includes other promising treatments for rare diseases such as acute myeloid leukemia and viral infections. With a dedicated team of scientists, researchers, and clinicians, BCRX is committed to advancing its pipeline and making a positive impact on the lives of patients around the world. The company's strong financial performance, with steady revenue growth and well-managed expenses, demonstrates its efficient and sustainable business model. BCRX's dedication to innovation, patient-centric approach, and strong financial position make it a promising and reputable company in the biotechnology industry.